Hepatitis B biomarkers: Clinical significance of the old and the new

Current Hepatitis Reports

Volumn 9, Issue 4, 2010, Pages 187-196

  Duarte Rojo, Andrés ^a   Feld, Jordan J ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

Biomarkers; Chronic hepatitis B; Cirrhosis; Genotype; HBeAg; HBsAg; Hepatocellular carcinoma; Transient elastography; Viral load

Indexed keywords

ALANINE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; CYSTEINE; GAMMA GLUTAMYLTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HYALURONIC ACID; THREONINE; VALINE; VIRUS DNA; VIRUS RNA;

AMINO ACID SUBSTITUTION; CLINICAL DECISION MAKING; DISEASE ACTIVITY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ELASTOGRAPHY; GENE MUTATION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOREGULATION; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER FIBROSIS; NON INVASIVE MEASUREMENT; PATIENT CARE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; SEROLOGY; THROMBOCYTE COUNT; VIRUS LOAD; VIRUS REPLICATION;

EID: 77958102049     PISSN: 15403416     EISSN: 15410706     Source Type: Journal    
DOI: 10.1007/s11901-010-0053-3     Document Type: Review

References (55)

1. CJ Chen HI Yang J Su, et al. 2006 Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 65 73 10.1001/jama.295.1.65 16391218 1:CAS:528:DC%2BD28XhtlKqtQ%3D%3D (Pubitemid 43042691)
2. E Cholongitas M Senzolo R Standish, et al. 2006 A systematic review of the quality of liver biopsy specimens Am J Clin Pathol 125 710 721 10.1309/W3XCNT4HKFBN2G0B 16707372
3. IR Wanless E Nakashima M Sherman 2000 Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis Arch Pathol Lab Med 124 1599 1607 11079009 1:STN:280:DC%2BD3M%2FkvFygtA%3D%3D
4. V Mallet V Dhalluin-Venier C Roussin, et al. 2009 The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B Aliment Pharmacol Ther 29 409 415 10.1111/j.1365-2036.2008.03895.x 19035983 1:STN:280:DC%2BD1M%2FlvFaisA%3D%3D
5. P Halfon M Munteanu T Poynard 2008 Fibrotest-Actitest as a noninvasive marker of liver fibrosis Gastroenterol Clin Biol 32 Suppl 1 22 39 10.1016/S0399-8320(08)73991-5 18973844
6. Y Ngo Y Benhamou V Thibault, et al. 2008 An accurate definition of the status of inactive hepatitis B virus carrier by a combination of biomarkers (fibrotest-actitest) and viral load Plos One 3 e2573 10.1371/journal.pone. 0002573 18596917 1:CAS:528:DC%2BD1cXoslWhsL8%3D
7. BK Kim DY Kim JY Park, et al. 2010 Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients Liver Int 30 546 553 10.1111/j.1478-3231.2009.02192.x 20074094
8. L Castera X Forns A Alberti 2008 Noninvasive evaluation of liver fibrosis using transient elastography J Hepatol 48 835 847 10.1016/j.jhep.2008.02.008 18334275
9. J Stebbing L Farouk G Panos, et al. 2010 A meta-analysis of transient elastography for the detection of hepatic fibrosis J Clin Gastroenterol 44 214 219 10.1097/MCG.0b013e3181b4af1f 19745758
10. B Coco F Oliveri AM Maina, et al. 2007 Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases J Viral Hepat 14 360 369 10.1111/j.1365-2893.2006.00811.x 17439526 1:STN:280:DC%2BD2s3jtFamtQ%3D%3D (Pubitemid 46587854)
11. U Arena F Vizzutti G Corti, et al. 2008 Acute viral hepatitis increases liver stiffness values measured by transient elastography Hepatology 47 380 384 10.1002/hep.22007 18095306 1:CAS:528:DC%2BD1cXitF2ltb0%3D (Pubitemid 351280705)
12. SU Kim 2010 Kim do Y, Park JY, et al.: How can we enhance the performance of liver stiffness measurement using fibroscan in diagnosing liver cirrhosis in patients with chronic hepatitis B? J Clin Gastroenterol 44 66 71 10.1097/MCG.0b013e3181a95c7f 19609218
13. HL Chan GL Wong PC Choi, et al. 2009 Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (fibroscan) for liver fibrosis in chronic hepatitis B J Viral Hepat 16 36 44 10.1111/j.1365-2893.2008.01037.x 18673426
14. L Castéra B Le Bail F Roudot-Thoraval, et al. 2009 Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (Fibroscan) with standard laboratory tests and non-invasive scores J Hepatol 50 59 68 10.1016/j.jhep.2008. 08.018 19013661
15. GL Wong VW Wong PC Choi, et al. 2010 Development of a noninvasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B Aliment Pharmacol Ther 31 1095 1103 20180785
16. D Prati E Taioli A Zanella, et al. 2002 Updated definitions of healthy ranges for serum alanine aminotransferase levels Ann Intern Med 137 1 10 12093239 1:CAS:528:DC%2BD38Xls1entbc%3D
17. HC Kim CM Nam SH Jee, et al. 2004 Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study BMJ 328 983 10.1136/bmj.38050.593634.63 15028636 1:CAS:528: DC%2BD2cXksFOmtbs%3D
18. • Ruhl CE, Everhart JE: Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009, 136:477-485.e11. The study confirms that lower thresholds for the upper limit of normal of ALT apply in North America and influence mortality.
19. AS Lok BJ McMahon 2009 Chronic hepatitis B: update 2009 Hepatology 50 661 662 10.1002/hep.23190 19714720
20. UH Iloeje HI Yang J Su, et al. 2006 Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group: Predicting cirrhosis risk based on the level of circulating hepatitis B viral load Gastroenterology 130 678 686 10.1053/j.gastro.2005.11.016 16530509 (Pubitemid 43374518)
21. - CHB, reinforcing that this agent has utility in this disease setting.
22. EH Buster BE Hansen GK Lau, et al. 2009 Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa Gastroenterology 137 2002 2009 10.1053/j.gastro.2009.08.061 19737568 1:CAS:528:DC%2BD1MXhs1SisrzJ
23. MF Yuen HJ Yuan DK Wong, et al. 2005 Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications Gut 54 1610 1614 10.1136/gut.2005.065136 15871997 (Pubitemid 41531781)
24. EQ Chen FJ Huang LL He, et al. 2010 Histological changes in Chinese chronic hepatitis B patients with ALT lower than two times upper limits of normal Dig Dis Sci 55 432 437 10.1007/s10620-009-0724-5 19241166
25. HI Yang SN Lu YF Liaw, et al. 2002 Hepatitis B e antigen and the risk of hepatocellular carcinoma N Engl J Med 347 168 174 10.1056/NEJMoa013215 12124405 1:CAS:528:DC%2BD38Xlt12jsLw%3D (Pubitemid 34764820)
26. BJ McMahon P Holck L Bulkow M Snowball 2001 Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus Ann Intern Med 135 759 768 11694101 1:STN:280:DC%2BD3MnovVOgtA%3D%3D
27. YF Liaw DI Tai CM Chu TJ Chen 1988 The development of cirrhosis in patients with chronic type B hepatitis: a prospective study Hepatology 8 493 496 10.1002/hep.1840080310 3371868 1:STN:280:DyaL1c3is1CmtQ%3D%3D
28. YS Hsu RN Chien CT Yeh, et al. 2002 Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B Hepatology 35 1522 1527 10.1053/jhep.2002.33638 12029639 (Pubitemid 34966908)
29. CM Chu YF Liaw 2007 Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion J Viral Hepat 14 147 152 10.1111/j.1365-2893.2006.00810.x 17305879
30. CT Wai RJ Fontana 2004 Clinical significance of hepatitis B virus genotypes, variants, and mutants Clin Liver Dis 8 321 352 10.1016/j.cld.2004.02. 006 15481343 (Pubitemid 38748607)
31. G Fattovich N Olivari M Pasino, et al. 2008 Long-term outcome of chronic hepatitis B in caucAsian patients: mortality after 25 years Gut 57 84 90 10.1136/gut.2007.128496 17715267 1:STN:280:DC%2BD2sjltlyksQ%3D%3D
32. YC Chen CM Chu YF Liaw 2010 Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B Hepatology 51 435 444 19918971
33. YF Yang W Zhao YD Zhong, et al. 2009 Interferon therapy in chronic hepatitis B reduces progression to cirrhosis and hepatocellular carcinoma: a meta-analysis J Viral Hepat 16 265 271 10.1111/j.1365-2893.2009.01070.x 19220736
34. SH Ahn YN Park JY Park, et al. 2005 Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance J Hepatol 42 188 194 10.1016/j.jhep.2004.10.026 15664243 1:CAS:528: DC%2BD2MXmvFSqtQ%3D%3D (Pubitemid 40143464)
35. J Simonetti L Bulkow BJ McMahon, et al. 2010 Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus Hepatology 51 1531 1537 20087968
36. MF Yuen Y Tanaka N Shinkai, et al. 2008 Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels Gut 57 98 102 10.1136/gut.2007.119859 17483190 1:CAS:528:DC%2BD1cXitVKqt78%3D
37. JD Chen HI Yang UH Iloeje, et al. 2010 Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death Gastroenterology 138 1747 1754 10.1053/j.gastro.2010.01.042 20114048
38. MF Yuen DK Wong J Fung, et al. 2008 HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma Gastroenterology 135 1192 1199 10.1053/j.gastro.2008.07.008 18722377 1:CAS:528:DC%2BD1cXht12lurrP
39. R Moucari A Korevaar O Lada, et al. 2009 High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study J Hepatol 50 1084 1092 10.1016/j.jhep.2009.01.016 19376603 1:CAS:528:DC%2BD1MXlslWmsr4%3D
40. MR Brunetto F Moriconi F Bonino, et al. 2009 Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B Hepatology 49 1141 1150 10.1002/hep.22760 19338056 1:CAS:528:DC%2BD1MXkslSqu7g%3D
41. TJ Liang 2009 Hepatitis B: the virus and disease Hepatology 49 Suppl S13 S21 10.1002/hep.22881 19399811 1:CAS:528:DC%2BD1MXlvFKqsL4%3D
42. S Chevaliez M Bouvier-Alias S Laperche JM Pawlotsky 2008 Performance of the cobas ampliprep/cobas taqman real-time PCR assay for hepatitis B virus DNA quantification J Clin Microbiol 46 1716 1723 10.1128/JCM.01248-07 18287319 1:CAS:528:DC%2BD1cXmvV2mtr8%3D (Pubitemid 351657219)
43. HJ Yuan MF Yuen 2005 Ka-Ho Wong D, et al.: The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B J Viral Hepat 12 373 379 10.1111/j.1365-2893.2005.00603.x 15985007 (Pubitemid 40961476)
44. YC Chen CM Chu CT Yeh YF Liaw 2007 Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study Hepatol Int 1 267 273 10.1007/s12072-007-5001-0 19669348
45. JJ Feld M Ayers D El-Ashry, et al. 2007 Hepatitis B virus DNA prediction rules for hepatitis B e antigen-negative chronic hepatitis B Hepatology 46 1057 1070 10.1002/hep.21811 17654702 1:CAS:528:DC%2BD2sXht1aksr3L (Pubitemid 350147802)
46. CJ Chu M Hussain AS Lok 2002 Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection Hepatology 36 1408 1415 12447866 1:CAS:528:DC%2BD38Xps1ylurs%3D
47. European Association for the Study of the Liver 2009 EASL clinical practice guidelines: management of chronic hepatitis B J Hepatol 50 227 242 10.1016/j.jhep.2008.10.001
48. YF Liaw N Leung JH Kao, et al. 2008 Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update Hepatol Int 2 263 283 10.1007/s12072-008-9080-3 19669255
49. M Perquin JG Reijnders NP Zhang, et al. 2009 HBeAg seroconversion during nucleos(t)ide analogue treatment does not lead to durable remission of chronic hepatitis B Hepatology 5 S407A
50. AB van Nunen BE Hansen DJ Suh, et al. 2003 Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase Gut 52 420 424 10.1136/gut.52.3.420 12584227 (Pubitemid 36250065)
51. HL Chan AY Hui ML Wong, et al. 2004 Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma Gut 53 1494 1498 10.1136/gut.2003.033324 15361502 (Pubitemid 39265273)
52. SE Livingston JP Simonetti LR Bulkow, et al. 2007 Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F Gastroenterology 133 1452 1457 10.1053/j.gastro.2007.08.010 17920063 1:CAS:528:DC%2BD2sXhsVGqtr%2FF (Pubitemid 350029740)
53. SE Livingston JP Simonetti BJ McMahon, et al. 2007 Hepatitis B virus genotypes in Alaska native people with hepatocellular carcinoma: preponderance of genotype F J Infect Dis 195 5 11 10.1086/509894 17152003 1:CAS:528: DC%2BD2sXpslSgsw%3D%3D (Pubitemid 44958221)
54. EH Buster HJ Flink Y Cakaloglu, et al. 2008 Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b Gastroenterology 135 459 467 10.1053/j.gastro.2008.05.031 18585385 1:CAS:528:DC%2BD1cXhtVCqsL%2FK
55. S Liu H Zhang C Gu, et al. 2009 Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis J Natl Cancer Inst 101 1066 1082 10.1093/jnci/djp180 19574418 1:CAS:528: DC%2BD1MXpvF2qtbY%3D